André C. Ferreira^{1,2,10#*,} Vinicius Cardoso Soares^{1,9#}, Isaclaudia G. de Azevedo-

Quintanilha¹, Suelen da Silva Gomes Dias¹, Natalia Fintelman-Rodrigues^{1,10}, Carolina Q.

induces inflammasome-dependent 1 SARS-CoV-2 pyroptosis and

downmodulation of HLA-DR in human monocytes 2

3

4

5

Sacramento^{1,10}, Mayara Mattos^{1,10}, Caroline S. de Freitas^{1,10}, Jairo R. Temerozo^{3,4}, Lívia 6 Teixeira¹, Eugenio Damaceno Hottz^{1,5}, Ester A Barreto¹, Camila R. R. Pão¹, Lohanna 7 Palhinha¹, Milene Miranda⁶, Dumith Chequer Bou-Habib^{3,4}, Fernando A. Bozza^{7,8}, 8 Patrícia T. Bozza¹, Thiago Moreno L. Souza^{1,10*} 9 10 11 1 - Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação 12 Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil. 13 2 - Laboratório de Pesquisa Pré-clínica - Universidade Iguaçu, Nova Iguaçu, RJ, Brazil. 14 3 - Laboratório de Pesquisas sobre o Timo, IOC, Fiocruz, Rio de Janeiro, RJ, Brazil. 15 4 - National Institute for Science and Technology on Neuroimmunomodulation, Oswaldo 16 Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil. 17 5 – Laboratório de Imunotrombose, Departamento de Bioquímica, Universidade Federal de Juiz de Fora, Juiz de Fora, MG, Brazil. 18 19 6 – Laboratório de Vírus Respiratório e do Sarampo, IOC, Fiocruz, Rio de Janeiro, RJ, 20 Brazil. 21 7 - Instituto Nacional de Infectologia Evandro Chagas, Fiocruz, Rio de Janeiro, RJ, 22 Brazil. 23 8 – Instituto D'or de Pesquisa e Ensino, Rio de Janeiro, RJ, Brazil. 24 9 - Program of Immunology and Inflammation, Federal University of Rio de Janeiro, 25 UFRJ, Rio de Janeiro, RJ, Brazil. 10 - Centro De Desenvolvimento Tecnológico Em Saúde (CDTS), Fiocruz, Rio de 26 27 Janeiro, Brasil. 28 29 # These authors contributed equally to this work 30 * corresponding author

- 31
- 32

33 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

34 Abstract

35 Infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has 36 been associated with leukopenia and uncontrolled inflammatory response in critically ill 37 patients. A better comprehension of SARS-CoV-2-induced monocyte death is essential 38 for the identification of therapies capable to control the hyper-inflammation and reduce 39 viral replication in patients with COVID-19. Here, we show that SARS-CoV-2 induces 40 inflammasome activation and cell death by pyroptosis in human monocytes, 41 experimentally infected and from patients under intensive care. Pyroptosis was dependent 42 on caspase-1 engagement, prior to IL-1ß production and inflammatory cell death. 43 Monocytes exposed to SARS-CoV-2 downregulate HLA-DR, suggesting a potential 44 limitation to orchestrate the immune response. Our results originally describe 45 mechanisms by which monocytes, a central cellular component recruited from peripheral 46 blood to respiratory tract, succumb to control severe 2019 coronavirus disease (COVID-47 19).

48 Author summary

49 Since its emergence in China in late 2019, severe acute respiratory syndrome 50 coronavirus 2 (SARS-CoV-2) has caused thousands of deaths worldwide. Currently, the 51 number of individuals infected with SARS-CoV-2 and in need of antiviral, anti-52 inflammatory, anticoagulant and more invasive treatments has overwhelmed the health 53 systems worldwide. In our study, we found that SARS-CoV-2 is capable of inducing 54 inflammatory cell death in human monocytes, one of the main cell types responsible for 55 anti-SARS-CoV-2 immune response. As a consequence of this intracellular inflammatory 56 mechanism (inflammasome engagement), an exacerbated production of inflammatory 57 mediators occurs. The infection also decreases the expression of HLA-DR in monocytes, 58 a molecule related to the orchestration of the immune response in case of viral infections. 59 We also demonstrated that the HIV-1 protease inhibitor, atazanavir (ATV), prevented the uncontrolled inflammatory response, cell death and reduction in HLA-DR expression in 60 61 SARS-CoV-2-infected monocytes. Our study provides relevant information on the effects of SARS-CoV-2 infection on human monocytes, as well as on the effect of ATV in 62 63 preventing these pathological effects on the host.

64

65

66 Introduction

67 Severe acute respiratory coronavirus 2 (SARS-CoV-2), the etiological agent of the 2019 coronavirus disease (COVID-19), emerged in China, causing a major public 68 69 health burden in decades. Patients with COVID-19 may develop an asymptomatic or mild 70 disease or be affected by the life threatening acute respiratory distress syndrome (ARDS), 71 which is characterized by elevated serum levels of proinflammatory mediators, the 72 cytokine storm (1-3). In the respiratory tract of patients with severe COVID-19, 73 monocytes/macrophages may be the main source of uncontrolled levels of the pro-74 inflammatory mediators TNF- α and IL-6 (4). Plasmatic levels of IL-6 have been 75 associated with mortality, intensive care admission and hospitalization, representing a 76 poor prognostic factor for COVID-19 (5). The uncontrolled inflammation promoted by 77 SARS-CoV-2 in severe COVID-19 is not acute, it negatively associates with viral loads 78 in nasopharyngeal swabs and represents an important event from 7 to 10 days after onset 79 of illness (6,7). The SARS-CoV-2-induced cytokine storm associates with intense cell 80 death (8,9).

81 There are various mechanisms involved in cell death, which are differently 82 engaged from development to responses to infection (10). For certain diseases, such as 83 COVID-19, in which the immunopathogenesis mechanisms associate with poor clinical 84 outcomes, controlling the way cells collapse to infection is vital for the host (10). For 85 example, cell death from necrosis, which can occur from necroptosis to pyroptosis, tends 86 to exacerbate inflammation due to the rupture of the cellular plasma membrane. 87 Pyroptosis, in particular, begins with the activation of the inflammasome, an intracellular 88 structure that involves several intracellular molecules such as caspase-1(10,11), leads to 89 leakage of the cytoplasmic content, favors inflammatory infiltrate (11) and amplifies of 90 the inflammatory response (12). These mechanisms of cell death contrasts with apoptosis, 91 a more controlled process that maintain the host's homeostasis.

In severe COVID-19, the cytokine storm associates with high levels of tissue insult, judged by increased levels lactate dehydrogenase (LDH) and D-dimer in the plasma (6–8). Moreover, high LDH levels and leukopenia in severe COVID-19 points out that white cells loses the integrity of plasma membrane (6–8). Among these cells,

96 monocytes should orchestrate the equilibrium between innate and adaptative immune 97 responses, which may be presumably affected during cytokine storm. Indeed, severe 98 immune dysregulation with low antigen presenting capacity is evidenced by reduced 99 expression of HLA-DR in monocytes during COVID-19, which is strongly associated 100 with severe respiratory failure (4).

101 The leukopenia of patients with severe COVID-19 seem to precede the cytokine 102 storm (13-18). Moreover, in other virus-induced cytokine storm episodes in the 103 respiratory tract, such as induced by influenza A virus, monocytes and macrophages are 104 severely affected (13). Thus, we hypothesized that the monocyte cell death induced by 105 SARS-COV-2 exacerbates the production of inflammatory cytokines, as well as impairs 106 the immune balance in the hosts. In fact, we found that SARS-CoV-2 triggers the activation of the inflammasome, leading to pyroptosis in human monocytes, by 107 108 experimental or natural infection. Pyroptosis was dependent on caspase-1 engagement, 109 prior to IL-1ß production and dysregulation of cytokine release. Monocytes that survive 110 after SARS-CoV-2 challenge downregulate HLA-DR, being less likely to properly orchestrate the immune response. Finally, we show that the reproposed antiviral drug 111 112 atazanavir (ATV) could block this deleterious loop in favor of the host.

113 Material and Methods

114 Reagents

115 Atazanavir (ATV) and Ribavirin were received as donations from Instituto de 116 Tecnologia de Fármacos (Farmanguinhos, Fiocruz). The antiviral Lopinavir/ritonavir 117 (4:1 proportion) was pruchased from AbbVie (Ludwingshafen, Germany). ELISA assays 118 were purchased from R&D Bioscience. Lipopolysacchadides - LPS, adenosine 119 triphosphate (ATP), the specific inhibitor of caspase-1 (AC-YVAD-CMK), pan-caspase 120 inhibitor (ZVAD-FMK), RIPK1 (Necrostatin-1 – Nec-1) and IL-1 receptor (IL-1RA) 121 were all purchased from Sigma-Aldrich (St. Louis, MO, USA). All small molecule 122 inhibitors were dissolved in 100 % dimethylsulfoxide (DMSO) and subsequently diluted at least 10⁴-fold in culture or reaction medium before each assay. The final DMSO 123 124 concentrations showed no cytotoxicity. The materials for cell culture were purchased 125 from Thermo Scientific Life Sciences (Grand Island, NY), unless otherwise mentioned.

126

127 Cells and Virus

128 African green monkey kidney (Vero, subtype E6) cells were cultured in DMEM 129 high glucose supplemented with 10 % fetal bovine serum (FBS; HyClone, Logan, Utah) 130 and 100 U/mL penicillin, and 100 μ g/mL streptomycin (P/S). Vero cells were incubated 131 at 37°C in 5 % CO₂ atmosphere.

Human primary monocytes were obtained through plastic adherence of peripheral blood mononuclear cells (PBMCs), which were obtained from buffy coat preparations of healthy donors by density gradient centrifugation (Ficoll-Paque, GE Healthcare). In brief, PBMCs (2.0×10^6 cells) were plated onto 48-well plates (NalgeNunc) in RPMI-1640 without serum for 2 to 4 h; then, non-adherent cells were removed by washing and the remaining monocytes were maintained in DMEM with 5% human serum (HS; Millipore) and penicillin/streptomycin.

139 SARS-CoV-2 was isolated and expanded on Vero E6 cells from a nasopharyngeal 140 swab of a confirmed case from Rio de Janeiro, Brazil. Experiments were performed after one passage in cell culture, when Vero E6 cells with DMEM plus 2% FBS in 150 cm² 141 flasks were incubated at 37 °C in 5 % CO₂ atmosphere. Cytopathic effect was observed 142 daily and peaked 4 to 5 days after infection. All procedures related to virus culture were 143 144 handled at biosafety level 3 (BSL3) multiuser facility, according to WHO guidelines. 145 Virus titers were determined as the tissue culture infectious dose at 50% (TCID50/mL). 146 Virus stocks were kept in -80 °C ultralow freezers. The virus strain was sequenced to 147 confirm the virus identity and its complete genome is publicly deposited (GenBank 148 accession no. MT710714).

149 **Yield-reduction assay**

Human primary monocytes were infected with multiplicity of infection (MOI) of 0.01 at density of $2-8 \times 10^5$ cells/well in 48-well culture plates, depending on the total cell number from each donor. After 1 h at 37 °C, cells were washed, and various concentrations of compounds were added in DMEM with 2% FBS. After 48 h, the

supernatants were harvested and virus replication was quantified by real time RT- PCRand infectious titers by TCID50/mL.

156 Virus titration

157 Monolayers of Vero cells $(2 \times 10^4 \text{ cell/well})$ in 96-well culture plates were infected 158 with log- based dilutions of the supernatants containing SARS-CoV-2 for 1 h at 37°C. 159 The cells were washed and fresh medium with 2% FBS was added. After 3 to 5 days, the 160 cytopathic effects were scored in at least 10 replicates per dilution by independent readers, 161 who were blind with respect to source of the supernatant. Reed and Muench scoring 162 method was employed to determine TCID50/mL.

163 Flow cytometer analysis

For flow cytometry analysis, monocytes were diluted in labelling buffer (10^6 cells/mL). Then, 100 µL of cell samples were marked with 5 µL of AnnexinV and PI for 15 minutes for cell death evaluation. Around 10,000 gated events were acquired using FACSCalibur and the analysis was performed using the CellQuest software. Monocytes were gated through cell size (foward light scatter, FSC) and granularity (side light scatter, SSC) analysis.

Human monocytes were stained for caspase-1 activity with FAM-YVAD-FMK (fluorescent-labeled inhibitor of caspase-1 [FLICA] and FAM-FLICA Caspase-3/7 activity or HLA-DR APC.H7 or IgG APC.H7. Caspase-1 and caspase-3/7 activity was determined via flow cytometry (FACSCalibur) by detecting FLICA fluorescence and expression of HLA-DR as mean fluorescence intensity (MFI) value for each sample. Acquisition of data was set to count a total of 10,000 events, and the FLOWJO software package was used to analyze the data.

177 Microscopic analysis

Human primary monocytes were plated on glass coverslips at density of $2-8 \times 10^5$ cells/well in 48-well plates. Infection was performed for 2 h at 37 °C and then fresh medium with 2% FBS was added. After 24 h, the cells were washed with Binding buffer and stained with PI (0.5 µg/mL) for 5 minutes. Next, the cells were fixed with 3.7% formaldehyde for 30 minutes at room temperature. The nuclei were stained with DAPI

- 183 $(1\mu g/mL)$ for 5 min and the coverslips were mounted using an antifade mounting medium
- 184 (VECTASHIELD). Fluorescence was analyzed by fluorescence microscopy with an x100
- 185 objective lens (Olympus, Tokyo, Japan).

186 Measurements Inflammatory Mediators and cell death marker

187 The levels of IL-1 β , TNF- α , IL-6, IL-8 and LDH were quantified in the culture 188 supernatants from infected and uninfected monocytes using ELISA kits, according to the 189 manufacturer's intructions (R&D System).

Extracellular lactate dehydrogenase (LDH) was quantified using Doles[®] kit according to manufacturer's instructions. In brief, cell culture supernatants were centrifuged at 5,000 rpm for 1 minute, to remove cellular debris, and then 25 μ L were placed into 96-well plates and incubated with 5 μ L of ferric alum and 100 μ L of LDH substrate for 3 minutes at 37 °C. Nicotinamide adenine dinucleotide (NAD, oxidized form) was added followed by the addition of a stabilizing solution. After 10 minutes, the reaction was read in a spectrophotometer at 492 nm.

197 Western blot assay

198 Cellular extracts of 1x10⁶ cells were homogenized in the RIPA lysis buffer in the 199 presence of proteinase inhibitor cocktail (Roche), and the protein levels were measured 200 by BCA protein assay kit. A total of 20 µg of protein was loaded onto a 10% sodium 201 dodecyl sulfate polyacrylamide gel (SDS-PAGE) for separation by electrophoresis and 202 the protein bands were then transferred to a polyvinylidene difluoride membranes 203 (ImmobilonP-SQ, Millipore). The membranes were blocked with 5 % albumin diluted in 204 Tris-buffered saline containing 0.05 % of Tween 20 for 2 hours at room temperature and 205 incubated with the specific primary antibodies (Cell Signaling Technology), to detect pro-206 caspase-1 and cleaved-caspase-1, after overnight incubation at 4 °C. After washing, 207 membranes were incubated with secondary antibodies (IRDye® 800CW Goat-anti-208 Mouse and IRDye® 680LT Goat anti-Rabbit IgG Antibody, LI-COR, Lincoln) for 30 209 minutes at RT. The protein bands were visualized by digital fluorescence 210 (Odyssey[®] CLx Imaging System), and protein density was analyzed by the ImageJ 211 software. All the data were normalized by β -actin expression quantification.

213 Human subjects.

214 We prospectively enrolled severe COVID19 RT-PCR-confirmed cases, as well as 215 SARS-CoV-2-negative healthy controls. Blood samples were obtained from 12 patients 216 with severe COVID-19 within 72 hours from intensive care unit (ICU) admission in two 217 reference centers (Instituto Estadual do Cérebro Paulo Niemeyer and Hospital Copa Star, 218 Rio de Janeiro, Brazil). Severe COVID-19 was defined as critically ill patients presenting 219 viral pneumonia on computed tomography scan and in mechanical ventilation. All 220 patients had SARSCoV-2 confirmed diagnostic through RT-PCR of nasal swab or 221 tracheal aspirates. Peripheral vein blood was also collected from 8 SARS-CoV-2-negative 222 healthy control participants as tested by RT-PCR on the day of blood sampling. The characteristics of severe (n = 12), and control (n = 8) participants are presented in Table 223 224 1. Severe COVID-19 patients usually present older age and higher prevalence of 225 comorbidities as obesity, cardiovascular diseases and diabetes as in previously reported 226 patient cohorts. In the present study, the SARS-CoV-2-negative control group was 227 designed to include subjects of older age and chronic non-communicable diseases, so it 228 is matched with critically ill COVID-19 patients (Table 1). Patients with acute respiratory distress syndrome (ARDS) were managed with neuromuscular blockade and a protective 229 230 ventilation strategy that included low tidal volume (6 mL/kg of predicted body weight) 231 and limited driving pressure (less than 16 cmH2O) as well as optimal PEEP calculated 232 based on the best lung compliance and PaO₂/FiO₂ ratio. In those with severe ARDS and 233 PaO₂/FiO₂ ratio below 150 despite optimal ventilatory settings, prone position was 234 initiated. Our management protocol included antithrombotic prophylaxis with enoxaparin 235 40 to 60 mg per day. Patients did not receive routine steroids, antivirals or other anti-236 inflammatory or anti-platelet drugs. The SARS-CoV-2- negative control participants 237 were not under anti-inflammatory or anti-platelet drugs for at least two weeks. All clinical 238 information were prospectively collected using a standardized form - ISARIC/WHO 239 Clinical Characterization Protocol for Severe Emerging Infections (CCPBR).

240 Ethics statement.

Experimental procedures involving human cells from healthy donors were performed with samples obtained after written informed consent and were approved by the Institutional Review Board (IRB) of the Oswaldo Cruz Foundation/Fiocruz (Rio de Janeiro, RJ, Brazil) under the number 397-07. The National Review Board approved the

study protocol (CONEP 30650420.4.1001.0008), and informed consent was obtainedfrom all participants or patients' representatives.

247 Statistical analysis

The assays were performed in blinded way. They were performed by one professional, codified and read by another fellow. All experiments were carried out at least three independent times, including a minimum of two technical replicates in each assay. The equations to fit the best curve were generated based on R^2 values ≥ 0.9 . Student's T-test was used to access statistically significant P values <0.05.

253 **Results**

254 SARS-CoV-2 promotes pyroptosis in human monocytes

255 To characterize the mechanism by which SARS-CoV-2 triggers monocyte death, 256 human primary monocytes were infected with SARS-CoV-2 or treated with LPS+ATP. 257 Next, cell death was analyzed by quantifying the LDH activity in the culture supernatant, 258 and by AnnexinV/propidium iodide (PI) cell labeling through for flow cytometry and 259 fluorescence microscopy. As shown in Figure 1A, SARS-CoV-2 increased LDH levels 260 similarly to the positive control, LPS+ATP (Figure 1A). Flow cytometry and fluorescence 261 microscopy images demonstrated higher percentages of PI⁺ cells in the infected cultures, 262 as well as a significant increase in mean fluorescence intensity (MFI). Both, LDH leak 263 and PI labeling characterize cell membrane disruption in human monocytes after SARS-264 CoV-2 infection (Figure 1B-E). These data suggest that SARS-CoV-2 infection can 265 induce cell death characterized by loss of plasma membrane integrity suggestive of 266 pyroptosis cell death.

267 SARS-CoV-2 induces pyroptosis in monocytes through inflammasome activation

To gain insights on the mechanisms of monocyte cell death in SARS-CoV-2 infection, we accessed caspase-1 activation - a key events that require inflammasome's proteolytic activity. Cells stimulated with LPS+ATP were used as a positive control of inflammasome activation. We observed that SARS-CoV-2 induced pro-caspase-1 cleavage, similarly to positive control (Figure 2A and 2B). To confirm these results, cells were labeled with FAM-YVAD-FLICA (as an indicative of caspase-1 activation) and

274 analyzed by flow cytometry. We found that SARS-CoV-2 infection induced the 275 activation of caspase-1 in monocytes in the same magnitude to the positive control group 276 (Figure 2C and 2D). Moreover, SARS-CoV-2-induced caspase-1 activation was a 277 specific event, since we did not observe activation of the apoptotic caspases-3 and -7 in 278 infected monocytes (Figure 2E and 2F). As caspase-1 activity is critical for the production 279 of IL-1 β (19.20), we measured the levels of this cytokine in our experiments. Our data 280 show that SARS-CoV-2 infection was able to increase IL-1ß production, this 281 phenomenon being prevented with pretreatment with AC-YVAD-CMK, and not altered 282 with a necroptosis inhibitor. (Figure 2G). Importantly, inhibition of IL-1R engagement 283 reduced SARS-CoV-2-mediated caspase-1 activation and LDH release (Figure S1), 284 suggesting that inflammasome-dependent IL-1ß secretion amplify caspase-1 activation 285 and pyroptosis in SARS-CoV-2 infection.

Inflammasome activation amplify pro-inflammatory cytokines secretion in infected monocytes

288 To evaluate the effect of the activation of inflammasome and pyroptosis on the 289 immune response, we quantified the production of key cytokines in the amplification of 290 the inflammatory process observed clinically in a patient during the course of the 291 infection with IL-6 and TNF-a. Remarkably, caspase-1 specific inhibition, but not pan-292 caspase or RIPK1 inhibitor, also led to lower levels of the pro-inflammatory cytokines 293 IL-6 and TNF- α , highlighting the participation of the caspase-1-IL-1 β axis in 294 inflammatory amplification during SARS-CoV-2 infection. (Figure 3A and 3B). To 295 confirm the effects in SARS-CoV-2 infection in the immune response, whether the 296 observed effect is specifically related to inflammasome activation, we evaluated the 297 production of IL-8, in which induction is independent of the inflammasomes pathway. 298 SARS-CoV-2 infection induced a higher IL-8 production, which was not prevented by 299 caspase-1 inhibition (Figure 3C). In addition, inhibition of IL-1R engagement reduced 300 SARS-CoV-2-mediated was able to significantly decrease the production of IL-1 β , IL-301 6, TNF- α and did not alter the production of IL-8 (Figure S2).

302

303

Infection with SARS-CoV-2 decreases the expression of HLA class II in human 304 305 monocytes independently of the activation of inflammasomes

306 To investigate the impact of inflammasome activation and cell death through 307 pyroptosis on the orchestration of anti-SARS-CoV-2 immune response, cells were then 308 marked with HLA-DR and analyzed by flow cytometry. We found that SARS-CoV-2 309 infection induced a decrease in HLA-DR expression in monocytes (Figure 4A and 4B). 310 However, the inhibition of caspase-1 (Figure 4A and 4B) and IL-1R engagement (Figure 311 S3) did not prevent the SARS-CoV-2-mediated decreasing of HLA expression. These 312 results suggest that even in disassociation with the engagement of SARS-CoV-2-induced 313 inflammasome activation, monocytes exposed to the new CoV will present limited ability 314 to orchestrate the immune response.

315 Atazanavir prevented inflammasome-dependent pyroptosis

316 Given our findings that pyroptosis and decreased HLA-DR expression are 317 triggered during SARS-CoV-2 replication, we tested whether atazanavir (ATV), an HIV 318 protease inhibitor recently shown to possess antiviral activity against the new CoV in 319 monocytes (17), could prevent these events. Flow cytometry analysis of SARS-CoV-2-320 infected monocytes treated with ATV demonstrated a significant reduction in caspase-1 321 activity, observed by the decreased FAM-YVAD-FLICA labeling (Figure 5A and 5B). 322 Other orally available repurposed anti-SARS-CoV-2 drugs, such as lopinavir (LPV) and 323 ribavirin (RBV), did not affect SARS-CoV-2-induced pyroptosis (Figure 5C). Moreover, 324 treatments with ATV did not alter the activity of caspase-1, -3 and -7 in monocytes 325 exposed to LPS and ATP, used as a positive control of pyroptosis (Figure S4), indicating 326 a specific antiviral activity of this drug. Consistently, treatment with ATV also reduced 327 the levels of IL-1 β , IL-6 and TNF- α in SARS-CoV-2-infected monocytes, when 328 compared to the untreated cells (Figure 5D-F). ATV did not interfere with the production 329 of IL-8, which is independent of inflammasome engagement (Figure 5G).

330 We then confirmed whether ATV can prevent SARS-CoV-2-induced pyroptosis. 331 Lower levels of LDH were detected in the supernatants of SARS-CoV-2-infected 332 monocytes treated with ATV, when compared to infected and untreated cells (Figure 5H). 333 The treatment with ATV was also able to prevent the decrease of HLA-DR expression in 334 infected monocytes (Figure 5I and J). LPV and RBV did not alter the HLA-DR expression

in monocytes infected with SARS-Cov-2 (Figure S5). Since ATV inhibits the early
proteolytic processing of viral antigens, an early event during SARS-CoV-2 replication,
this drug represented the most upstream process pharmacologically inhibited in this
investigation to prevent pyroptosis and HLA-DR knockdown.

Inflammasome activation and pyroptosis are risk factors in critically ill COVID-19 patients

341 To clinically validate our findings, we evaluated if monocytes obtained from 342 critically ill patients with COVID-19 would also display signals of inflammasome 343 engagement and pyroptosis. We observed that monocytes from COVID-19 patients had increased caspase-1 activation (Figure 6A and 6B) and significantly higher PI+ staining, 344 345 when compared to monocytes from healthy donors (HD) (Figure 6C and 6D). 346 Corroborating with our *in vitro* data, we also detected higher levels of IL-1 β in the plasma 347 of critically ill patients (Figure 6E). Therefore, the in vitro results from the previous 348 sections stand on the shoulders of the clinical relevance of monocytes in patients with 349 severe COVID-19.

350 SARS-CoV-2 infection induces inflammasome-dependent pyroptosis and 351 downmodulation of HLA-DR monocytes, which can be prevented by atazanavir

A representative scheme to summarize the effect of SARS-CoV-2 infection upon in the increase of TNF- α and IL-6 levels, as part of an immunodysregulation promoted by pyroptosis. SARS-CoV-2-induced pyropotosis engages inflammasomes, to activate caspase-1 and IL-1 β . Release of IL-1 β amplify the activation of inflammasomes during the SARS-CoV-2 infection. In parallel, SARS-CoV-2 also induces the HLA-DR downregulation. ATV prevented SARS-CoV-2-induced deleterious effects on monocyte biology.

359 **Discussion**

360 COVID-19 has caused in less than 8 months over 800,000 deaths worldwide (21) 361 and represent the major public health crisis of the beginning of 21st century, leading to an 362 unpredictable impact in global economics (22,23). SARS-CoV-2 infection triggers an 363 uncontrolled inflammatory response and marked leukopenia with consequent 364 lung/respiratory dysfunction, which are the characteristics of the most severe

365 manifestations of the COVID-19 (24,25). Similarly, to other respiratory viruses (26-29), 366 SARS-CoV-2 induces a cytokine storm, characterized by an uncontrolled inflammatory 367 response mediated by monocytes/macrophages, when they should orchestrate the 368 antiviral immune response (30). In this work, we demonstrate that SARS-CoV-2 infection 369 triggers inflammasome activation, increases IL-1ß secretion by monocytes, resulting in 370 pyroptotic cell death, which could be a key event for SARS-CoV-2 pathogenesis in 371 critically ill patients (31). This deleterious immune dysregulation loop triggered by 372 SARS-CoV-2 may be impaired by ATV.

373 Our results demonstrate that SARS-CoV-2 leads to an intense cell death in human 374 monocytes, observed by the increase in LDH release in infected cultures, as well as by 375 the higher number of PI⁺ cells when compared to uninfected controls. Even though the 376 pretreatment of infected monocytes with the pan-caspase inhibitor ZVAD-FMK 377 prevented IL-1 β secretion, it was not able to prevent the release of LDH. Indeed, others 378 have demonstrated that the treatment with ZVAD-FMK induces necroptosis in diverse 379 cell types (32-34). Notably, as pyroptosis is an inflammatory and programmed cell death 380 mediated by inflammasome and inflammatory caspase-1 activation (10,11), we 381 investigated the engagement and activation of these structures in human monocytes 382 infected with SARS-CoV-2. Activation of caspase-1 and increased production of IL-1ß 383 were observed in infected monocytes. This is correlated to the activation of 384 inflammasomes, because the pretreatment of infected monocytes with YVAD prevented 385 caspase-1 activation. These in vitro results are in accordance with the literature and with 386 our finding described here that indicate the formation of inflammasomes in patients with 387 severe COVID-19 (35). We also showed that the release of IL-1ß could be promoted by 388 the activation of inflammasomes during the SARS-CoV-2 infection, because blockage of 389 IL-1ß receptors reduced caspase-1 activation and cell death. These results corroborate 390 with studies showing that the increase in IL-1ß production is associated with severe 391 COVID-19 (36-38). Under our experimental conditions, the increase in IL-1ß precedes 392 the unbalanced IL-6 release. These information should not be neglected when considering 393 biopharmaceuticals to tackle cytokine storm in severe COVID-19.

Monocytes that survived from SARS-CoV-2 infection displayed decreased HLA-DR expression, which has also been described in monocytes isolated from COVID-19 patients (39,40). Our results suggest that this modulation of HLA expression is not

397 directly associated with the activation of inflammasomes, and may be involved by other 398 inflammatory pathways, since we and others have observed increased levels of IL-6 by 399 myeloid cells impairing HLA-DR membrane expression (41).

400 To stablish the clinical relevance of SARS-CoV-2-induced pyroptosis in 401 monocytes (41,41), we analyzed peripheral monocytes isolated from patients with severe 402 COVID-19. We found that the cells from the patients displayed higher caspase-1 403 activation, when compared with monocytes isolated from HD. Recent clinical data reveal 404 high levels of LDH and consistent leukopenia in critically ill COVID-19 patients 405 (6,7,35,42-44). Our data also demonstrate intense monocyte death in COVID-19 patients, 406 as detected through flow cytometry analyzes. Altogether, these data suggest that the 407 severity of COVID-19 may be associated with inflammasome activation in monocytes 408 that results in large amounts of IL-1ß and generates an excessive inflammatory response, 409 further characterized by high levels of IL-6 and TNF-α. Consistently, treatment with IL-410 1RA has been associated with clinical and inflammatory improvements in critically ill 411 COVID-19 patients (45). These results are in line with clinical case reports that demonstrate that monocytes/macrophages are key cells in the deleterious pro-412 413 inflammatory events that characterize the most serious cases of COVID-19 (46-49).

414 To the best of our knowledge, effective therapies for COVID-19 should ideally 415 combine antiviral/anti-inflammatory drugs to reduce viral load and to mitigate the 416 cytokine storm. In the present study, we showed that ATV, an antiretroviral approved in 417 2003 for HIV-1 treatment and previously described by us as having anti-SARS-CoV-2 418 effects in different cell types (including monocytes)(50), to block new CoV-induced 419 pyroptosis and HLA-DR knockdown in monocytes. In addition, ATV inhibited the 420 release of LDH and the production of IL-1B, f IL-6 and TNF-a from SARS-CoV-2-421 infected monocytes, which are key players in the cytokine storm associated with COVID-422 19 (51,52).

423 In this work, we originally describe that infection with SARS-CoV-2 can induce 424 pyroptotic cell death by inflammasome activation, which may be related to the intense 425 leukopenia and exacerbated inflammation seen in severe cases of the COVID-19. Since 426 there is no specific therapy for this disease, our results point out that ATV has a promising 427 therapeutic potential against SARS-CoV-2-induced cell death.

428 Acknowledgments and funding

429 We thank the Hemotherapy Service from Hospital Clementino Fraga Filho (Federal University of Rio de Janeiro, Brazil) for providing buffy-coats. This work was 430 431 supported by grants from Fundação de Amparo a Pesquisa do Estado do Rio de Janeiro 432 (FAPERJ), Inova Fiocruz, Conselho Nacional de Desenvolvimento Científico e 433 Tecnológico (CNPq) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 434 (CAPES) and Mercosur Fund for Structural Convergence (FOCEM, Mercosur, grant 435 number 03/11) granted for Thiago Moreno L. Souza, Patrícia T. Bozza, Fernando A. 436 Bozza and Dumith Chequer Bou-Habib. Funding was also provided by CNPq, CAPES 437 and FAPERJ through the National Institutes of Science and Technology Program (INCT) 438 to Carlos Morel (INCT-IDPN) and to Wilson Savino (INCT-NIM). Thanks are due to 439 Oswaldo Cruz Foundation/Fiocruz under the auspicious of Inova program. The funding 440 sponsors had no role in the design of the study; in the collection, analyses, or 441 interpretation of data; in the writing of the manuscript, and in the decision to publish the 442 results.

443 **References**

444	1.	Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, et al. Induction
445		of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by
446		COVID-19: anti-inflammatory strategies. Journal of biological regulators and
447		homeostatic agents. 2020.
448	2.	Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in
449		COVID-19. American Journal of Emergency Medicine. 2020.
450	3.	Li J, Fan J-G. Characteristics and Mechanism of Liver Injury in 2019

- 451 Coronavirus Disease. J Clin Transl Hepatol. 2020.
- 452 4. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K,
 453 Antoniadou A, Antonakos N, et al. Cell Host Microbe. 2020.
- 454 5. Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of
 455 mortality for patients with COVID-19 pneumonia caused by SARSCoV- 2: A
 456 prospective cohort study. Eur Respir J. 2020.

457	6.	Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors
458		for mortality of adult inpatients with COVID-19 in Wuhan, China: a
459		retrospective cohort study. Lancet. 2020.
460	7.	Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et
461		al. Virological assessment of hospitalized patients with COVID-2019. Nature.
462		2020.
463	8.	Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte
464		changes in mild versus severe SARS-CoV-2 infection: Review of 3939
465		COVID-19 patients in China and emerging pathogenesis and therapy
466		concepts. Journal of Leukocyte Biology. 2020.
467	9.	Chen Z, John Wherry E. T cell responses in patients with COVID-19. Nature
468		Reviews Immunology. 2020.
469	10.	Danthi P. Viruses and the Diversity of Cell Death. Annual Review of
470		Virology. 2016.
471	11.	Jorgensen I, Miao EA. Pyroptotic cell death defends against intracellular
472		pathogens. Immunological Reviews. 2015.
473	12.	Man SM, Karki R, Kanneganti TD. Molecular mechanisms and functions of
474		pyroptosis, inflammatory caspases and inflammasomes in infectious diseases.
475		Immunological Reviews. 2017.
476	13.	Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings
477		of COVID-19 associated with acute respiratory distress syndrome. Lancet
478		Respir Med. 2020.
479	14.	Han Y, Zhang H, Mu S, Wei W, Jin C, Xue Y, et al. Lactate dehydrogenase,
480		a Risk Factor of Severe COVID-19 Patients. medRxiv. 2020.
481	15.	Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN,
482		Politou M, et al. Hematological findings and complications of COVID-19.
483		American Journal of Hematology. 2020.
484	16.	Li YX, Wu W, Yang T, Zhou W, Fu YM, Feng QM, et al. [Characteristics of
485		peripheral blood leukocyte differential counts in patients with COVID-19].
486		Zhonghua nei ke za zhi. 2020.
487	17.	Ding X, Yu Y, Lu B, Huo J, Chen M, Kang Y, et al. Dynamic profile and
488		clinical implications of hematological parameters in hospitalized patients with
489		coronavirus disease 2019. Clin Chem Lab Med. 2020.

490	18.	Singh A, Sood N, Narang V, Goyal A. Morphology of COVID-19-affected
491		cells in peripheral blood film. BMJ Case Reports. 2020.
492	19.	Zalinger ZB, Elliott R, Weiss SR. Role of the inflammasome-related cytokines
493		Il-1 and Il-18 during infection with murine coronavirus. J Neurovirol. 2017.
494	20.	Franchi L, Eigenbrod T, Muñoz-Planillo R, Nuñez G. The inflammasome: A
495		caspase-1-activation platform that regulates immune responses and disease
496		pathogenesis. Nature Immunology. 2009.
497	21.	OPAS. COVID-19 (doença causada pelo novo coronavírus). Folha Inf. 2020.
498	22.	Dong E, Du H, Gardner L. An interactive web-based dashboard to track
499		COVID-19 in real time. The Lancet Infectious Diseases. 2020.
500	23.	Wissel BD, Van Camp PJ, Kouril M, Weis C, Glauser TA, White PS, et al. An
501		Interactive Online Dashboard for Tracking COVID-19 in U.S. Counties,
502		Cities, and States in Real Time. J Am Med Inform Assoc. 2020.
503	24.	Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, et al.
504		Longitudinal analyses reveal immunological misfiring in severe COVID-19.
505		Nature. 2020.
506	25.	Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19:
507		immunity, inflammation and intervention. Nature Reviews Immunology.
508		2020.
509	26.	Teijaro JR. The role of cytokine responses during influenza virus pathogenesis
510		and potential therapeutic options. Curr Top Microbiol Immunol. 2014.
511	27.	Szretter KJ, Gangappa S, Lu X, Smith C, Shieh W-J, Zaki SR, et al. Role of
512		Host Cytokine Responses in the Pathogenesis of Avian H5N1 Influenza
513		Viruses in Mice. J Virol. 2007.
514	28.	Peschke T, Bender A, Nain M, Gemsa D. Role of Macrophage Cytokines in
515		Influenza A Virus Infections. Immunobiology. 1993.
516	29.	Woo PCY, Tung ETK, Chan KH, Lau CCY, Lau SKP, Yuen KY. Cytokine
517		profiles induced by the novel swine-origin influenza A/H1N1 virus:
518		Implications for treatment strategies. J Infect Dis. 2010.
519	30.	Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T, et al. Should
520		we stimulate or suppress immune responses in COVID-19? Cytokine and anti-
521		cytokine interventions. Autoimmunity Reviews. 2020.

522	31.	Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical &
523		mortal COVID-19 cases: A systematic literature review and meta-analysis.
524		Journal of Infection. 2020.
525	32.	Siegmund D, Kums J, Ehrenschwender M, Wajant H. Activation of TNFR2
526		sensitizes macrophages for TNFR1-mediated necroptosis. Cell Death Dis.
527		2016.
528	33.	Kim SJ, Li J. Caspase blockade induces RIP3-mediated programmed necrosis
529		in Toll-like receptor-activated microglia. Cell Death Dis. 2013.
530	34.	Wu YT, Tan HL, Huang Q, Sun XJ, Zhu X, Shen HM. ZVAD-induced
531		necroptosis in L929 cells depends on autocrine production of TNF α mediated
532		by the PKC-MAPKs-AP-1 pathway. Cell Death Differ. 2011.
533	35.	Rodrigues S, de Sá KS, Ishimoto AY, Becerra A, Oliveira S, Almeida L, et al.
534		Inflammasome activation in COVID-19 patients 1 2 Tamara. medRxiv. 2020;
535	36.	Abbasifard M, Khorramdelazad H. The bio-mission of interleukin-6 in the
536		pathogenesis of COVID-19: A brief look at potential therapeutic tactics. Life
537		Sciences. 2020.
538	37.	Yao Z, Zheng Z, Wu K, Zheng J. Immune environment modulation in
539		pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and
540		SARS-CoV-2. Aging (Albany NY). 2020.
541	38.	Zhang Y, Li J, Zhan Y, Wu L, Yu X, Zhang W, et al. Analysis of serum
542		cytokines in patients with severe acute respiratory syndrome. Infect Immun.
543		2004.
544	39.	Ong EZ, Chan YFZ, Leong WY, Lee NMY, Kalimuddin S, Haja Mohideen
545		SM, et al. A Dynamic Immune Response Shapes COVID-19 Progression. Cell
546		Host Microbe. 2020.
547	40.	Laing AG, Lorenc A, del Molino del Barrio I, Das A, Fish M, Monin L, et al.
548		A dynamic COVID-19 immune signature includes associations with poor
549		prognosis. Nat Med [Internet]. 2020; Available from:
550		https://doi.org/10.1038/s41591-020-1038-6.
551	41.	Ohno Y, Kitamura H, Takahashi N, Ohtake J, Kaneumi S, Sumida K, et al. IL-
552		6 down-regulates HLA class II expression and IL-12 production of human
553		dendritic cells to impair activation of antigen-specific CD4+ T cells. Cancer
554		Immunol Immunother. 2016.

555	42.	Yap JKY, Moriyama M, Iwasaki A. Inflammasomes and Pyroptosis as
556		Therapeutic Targets for COVID-19. J Immunol. 2020.
557	43.	Yuan J, Zou R, Zeng L, Kou S, Lan J, Li X, et al. The correlation between
558		viral clearance and biochemical outcomes of 94 COVID-19 infected
559		discharged patients. Inflamm Res. 2020.
560	44.	Yan L, Zhang HT, Goncalves J, Xiao Y, Wang M, Guo Y, et al. An
561		interpretable mortality prediction model for COVID-19 patients. Nat Mach
562		Intell. 2020.
563	45.	Cauchois R, Koubi M, Delarbre D, Manet C, Carvelli J, Blasco VB, et al. Early
564		IL-1 receptor blockade in severe inflammatory respiratory failure
565		complicating COVID-19. Proc Natl Acad Sci. 2020.
566	46.	Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune
567		response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020.
568	47.	McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines
569		including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage
570		Activation Syndrome-Like Disease. Autoimmunity Reviews. 2020.
571	48.	Merad M, Martin JC. Pathological inflammation in patients with COVID-19:
572		a key role for monocytes and macrophages. Nature Reviews Immunology.
573		2020.
574	49.	Park MD. Macrophages: a Trojan horse in COVID-19? Nat Rev Immunol.
575		2020.
576	50.	Fintelman-Rodrigues N, Sacramento CQ, Lima CR, Silva FS da, Ferreira A,
577		Mattos M, et al. Atazanavir inhibits SARS-CoV-2 replication and pro-
578		inflammatory cytokine production. bioRxiv. 2020.
579	51.	Hantoushzadeh S, Norooznezhad AH. Possible Cause of Inflammatory Storm
580		and Septic Shock in Patients Diagnosed with (COVID-19). Arch Med Res.
581		2020.
582	52.	Hantoushzadeh S, Norooznezhad AH. Inappropriate Antibiotic Consumption
583		as a Possible Cause of Inflammatory Storm and Septic Shock in Patients
584		Diagnosed with Coronavirus Disease 2019 (COVID-19). Arch Med Res.
585		2020.
586 587		
587 588		
589		

590 FIGURE LEGENDS

591

592 Figure 1. SARS-Cov-2 induces monocyte cell death through pyroptosis. Human 593 monocytes were infected with SARS-CoV-2 (MOI 0.1) for 24 h. As a positive control, 594 monocytes were stimulated with LPS (500ng/mL) for 23 h and after this time, incubated 595 with ATP (2 mM) for 1 h. (A) Cell viability was assessed through the measurement of 596 LDH release in the supernatant of monocytes. (B, C and D) Monocytes' monolayers were 597 stained with propidium iodide (PI) plus Annexin V and pyroptotic cell death were 598 determine by flow cytometer analysis and (E) labeled with DAPI to visualize the nuclei 599 fluorescence microscopy. Images and Graph data are representative of six independent experiments. Data are presented as the mean \pm SEM * P < 0.05 versus control group 600 601 (MOCK).

602 Figure 2. SARS-CoV-2 induce inflammasome activation in human monocytes. 603 Human monocytes were pretreated with caspase-1 inhibitor (AC-YVAD-CMK -1μ M), 604 pan-caspase inhibitor (ZVAD-FMK - 10 µM) or necroptosis inhibitor (Nec-1 - 25 µM) 605 for 1 h and infected with SARS-Cov-2 (MOI 0.1) for 24 h. Monocytes were stimulated 606 with LPS (500ng/mL) for 23 h and after this time were stimulated with ATP (2 mM) for 607 1 h as a positive control group for the formation of inflammasomes and pyroptosis 608 induction. (A, B) Monocytes' monolayers were used for determination of the levels of 609 pro-caspase-1 and cleaved caspase-1 by western blot analysis. (C - F) Monocytes were 610 stained with FAM-YVAD-FLICA and FAM-FLICA to determine the caspase-1 and caspase-3/7 activity, respectively, by flow cytometry. (G) Cell culture supernatants were 611 612 collected for the measurement of the levels of IL-1β. Western blot, histogram and graph 613 data are representative of six independent experiments. Data are presented as the mean \pm 614 SEM # P < 0.05 versus infected and untreated group.

615 Figure 3. Inflammasome activation amplify pro-inflammatory cytokines secretion

616 in infected monocytes. Human monocytes were pretreated with caspase-1 inhibitor (AC-617 YVAD-CMK - 1 µM), pan-caspase inhibitor (ZVAD-FMK - 10 µM), necroptosis 618 inhibitor (Nec-1 - 25 μ M) or with inhibitor of IL-1 β receptor (IL-1RA - 1 μ M). 619 Monocytes were stimulated with LPS (500ng/mL) for 23 h and after this time were 620 stimulated with ATP (2 mM) for 1 h as a positive control group for the formation of 621 inflammasomes and pyroptosis induction. Cell culture supernatants were collected for the 622 measurement of the levels of (A) IL-6, (B) TNF- α and (C) IL-8. Graphs data are

623 representative of six independent experiments. Data are presented as the mean \pm SEM [#]

624 P < 0.05 versus infected and untreated group.

625 Figure 4. Infection with SARS-CoV-2 decreases the expression of HLA in human 626 monocytes independently of the activation of inflammasomes. Human monocytes were pretreated with caspase-1 inhibitor (AC-YVAD-CMK -1μ M) for 1 h and infected 627 628 with SARS-Cov-2 for 24 h. (A, B) Monocytes were stained with HLA-DR APC.H7 or 629 Isotype control APC.H7 to determine the HLA-DR expression by flow cytometry. Mean 630 fluorescence intensity (MFI) value for each sample was represented in graphics. 631 Histogram and graphs datas are representative of six independent experiments. Data are 632 presented as the mean \pm SEM * P < 0.05 versus uninfected group (MOCK).

633 Figure 5. Atazanavir prevented inflammasome-dependent pyroptosis. Human 634 monocytes were infected with SARS-Cov-2 and treated with atazanavir – ATV (10 μ M), 635 ribavirina (10 µM) or Lopinavir (10 µM) for 24 h. (A, B and C) Monocytes were stained 636 with FAM-YVAD-FLICA or FAM-FLICA and HLA-DR APC.H7 or IgG APC.H7 to 637 determine the caspase-1 and caspase-3/7 activity and HLA-DR expression, respectively 638 and analyzed by flow cytometry. (D - G) Culture supernatants were collected and the 639 levels of IL-1 β , IL-6, TNF- α and IL-8 were determined by ELISA. (H) Assessment of 640 cell viability through the measurement of LDH release in the supernatant of monocytes. 641 (I and J) Monocytes were stained with HLA-DR APC.H7 to determine the HLA-DR 642 expression by flow cytometry. Histogram and graphs datas are representative of six independent experiments. Data are presented as the mean \pm SEM * P < 0.05 versus control 643 644 group (MOCK); $^{\#} P < 0.05$ versus only infected group.

Figure 6. Inflammasome activation and pyroptosis are risk factors in critically ill COVID-19 patients. Monocytes isolated from blood samples of critically ill patients with COVID-19 and healthy donors. (A and B) monocytes were stained with FAM-YVAD-FLICA or (C and D) propidium iodide (PI) and analyzed by flow cytometry. (E) plasma was separated and the levels of IL-1β were determined by ELISA. Western blot, histogram and graphs datas are representative of 9 critically ill patients and 8 healthy donors. Data are presented as the mean \pm SEM * *P* < 0.05 *versus* healthy donors (HD).


- 652 Figure 7. Representative scheme of the SARS-CoV-2 infection in activation of
- 653 inflammasome and pyroptosis in monocyte with downregulation of HLA-DR expression
- and effects of ATV treatment in this phenomenon.


673


674 Table 1: Characteristics of COVID-19 patients and control subjects.


Characteristics ¹	Control (N=8)	Covid-19 (N=9)
Age, years	52.6 (47 - 60)	61 (33 – 79)
Sex, male	8 (100 %)	6 (66.7 %)
Respiratory support	F.	
Oxygen supplementation	0 (0 %)	3 (33.3 %)
Mechanical ventilation	0 (0 %)	6 (66.7 %)
SAPS 3		59.25 (31 - 75)
PaO2/FiO2 ratio	-	210.75 (87 - 509.5)
Vasopressor	-	3 (33.3 %)
Time from symptom onset to blood sample, days	-	10 (6 – 18)
Status on Jun 30th		
Dead) 4	5 (55.55 %)
Discharged	-	1 (11.1 %)
Hospitalized	-	3 (33.3 %)
Comorbidities		
Obesity	1 (11.1 %)	1 (11.1 %)
Hypertension	3 (33.3%)	3 (33.3 %)
Diabetes	0 (0%)	0 (0 %)
Cancer	0 (0%)	0 (0 %)
Chronic heart disease ²	0 (0%)	0 (0 %)
Presenting symptoms		
Cough	0 (0 %)	3 (33,3 %)
Fever	0 (0 %)	3 (33,3 %)
Dyspnea	0 (0 %)	4 (44,4 %)
Headache	0 (0 %)	0 (0 %)
Anosmia	0 (0 %)	0 (0 %)
Laboratory findings on admission	2	
Lymphocyte count, cells/mm ³		1,355.8 (552 - 2,564
Platelet count, x 1000/mm ³	(1)	169.6 (92 - 278)
Leukocytes	6 	8,036 (8.03-18,670)
C Reactive Protein, mg/L	-	14.78 (0.1 - 30.8)


- 702

























S2 Fig. Infection with SARS-CoV-2 decreases the expression of HLA in human monocytes independently of the IL-1ß activation. Human monocytes were pretreated with inhibitor of IL-1 β receptor (IL-1RA – 1 μ M) for 1 h and infected with SARS-Cov-2 for 24 h. Monocytes were stained with HLA-DR APC.H7 or IgG APC.H7 to determine the HLA-DR expression by flow cytometry. Mean fluorescence intensity (MFI) value for each sample was represented in graphics. Graphs datas are representative of four independent experiments. Data are presented as the mean \pm SEM [#] P < 0.05 versus uninfected group (MOCK).



1057 **S3 Fig. Evaluation of anti-inflammatory activity of ATV, LPV and ribavirin in LPS-induced monocytes.** Human monocytes were stimulated 1058 with LPS (500ng/mL) for 23 h and after this time were stimulated with ATP (2 mM) for 1 h as a positive control group for the formation of 1059 inflammasomes and pyroptosis induction. Simultaneously, cells were treated with atazanavir – ATV (10 μ M), LPV (10 μ M) or ribavirin (10 μ M) 1060 for 24 h. Monocytes were stained with FAM-YVAD-FLICA (blue) or FAM-FLICA (green) to determine the caspase-1 and caspase-3/7 activity 1061 and HLA-DR expression, respectively, and analyzed by flow cytometry. Histograms are representative of six independent experiments.



1105